EHang Holdings Ltd (EH) Stock News

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Insulet Corporation on behalf of investors who purchased securities between February 21, 2025 and May 26, 2026. The lawsuit alleges that Insulet failed to disclose defective manufacturing controls and safety risks. Two significant product corrections were announced in March and May 2026, resulting in substantial stock price declines of approximately 7% and 5% respectively. The deadline to request lead plaintiff appointment is August 31, 2026.

Julie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.

Monteverde & Associates PC is investigating Cross Country Healthcare's proposed sale to KL Criss Cross Intermediate, LLC for $13.25 per share in cash. The firm is encouraging shareholders to act before the July 16, 2026 vote to determine if the deal is fair.

Law firm Levi & Korsinsky has filed a class action lawsuit against Planet Fitness for allegedly providing false and misleading statements about customer acquisition and marketing metrics. The company's updated marketing campaign failed to resonate with its core demographic, leading to slower-than-expected membership growth in Q1 2026. Planet Fitness subsequently slashed full-year growth guidance and withdrew its three-year growth targets. The stock declined 31.19% on May 7, 2026, following the disappointing earnings announcement.

Brancous LP1, a shareholder of Braemar Hotels & Resorts, criticizes the Board for wasting company resources attacking shareholders instead of negotiating a lower Ashford termination payment. The shareholder claims the Board is pursuing a 'stealth liquidation' through asset sales to trigger a $480 million Change of Control payment to Ashford, which Brancous estimates at $7.00 per share. Brancous demands the Board declare a special dividend of at least $1.00 per share, renegotiate the Ashford payment, and allow shareholders to elect an independent Board.

A securities class action lawsuit has been filed against Nano-X Imaging (NNOX) alleging the company made false statements about operational efficiency and product demand while concealing poor manufacturing alignment, increased cash burn, and restructuring risks. The lawsuit covers investors who purchased securities between March 31, 2025 and April 17, 2026. The deadline to seek lead plaintiff status is August 11, 2026. The action was triggered after Nano-X reported a $33.4 million net loss in Q4 2025, including a $17.5 million impairment charge related to restructuring at its Korean facility, causing the stock to fall 24.39%.

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

Faruqi & Faruqi, LLP is investigating securities fraud claims against Erasca, Inc. (NASDAQ: ERAS) for allegedly making false statements about its ERAS-0015 drug candidate based on improper comparisons to Revolution Medicines' compound. The company disclosed patent infringement allegations and a patient death in Phase 1 trials on April 27, 2026, causing the stock to plummet from $21.49 to $9.90 per share over two trading days. Investors who purchased ERAS securities between January 14, 2025 and April 26, 2026 can seek lead plaintiff status by August 10, 2026.

A securities class action lawsuit has been filed against Peabody Energy Corporation for allegedly making false and misleading statements about its Centurion mine operations. The company provided overly positive guidance while concealing material operational challenges. Stock price declined significantly following corrective disclosures on March 30, 2026 (down 9.7%) and May 5, 2026 (down 5.7%) when the company revealed commissioning delays and reduced output expectations. The deadline to seek lead plaintiff status is August 24, 2026.

A federal securities class action has been filed against Lucid Group alleging that the company and its executives made false and misleading statements by concealing a supplier quality issue that significantly disrupted Lucid Gravity deliveries and overstating manufacturing capabilities. The lawsuit covers investors who purchased LCID stock between February 25, 2026 and April 13, 2026. The deadline to seek lead plaintiff appointment is July 28, 2026.

A securities class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) alleging that the company made false and misleading statements about its financial guidance. Embecta's stock plummeted 57.8% on May 5, 2026, after the company disclosed a revenue decline of over 14% and cut its fiscal year 2026 guidance, primarily due to weakness in pen needle sales. The deadline to seek lead plaintiff status is August 17, 2026.

Faruqi & Faruqi, LLP is investigating a federal securities class action against GeneDx Holdings Corp. (NASDAQ: WGS) for allegedly making false and misleading statements about its Fabric Genomics acquisition and overstating the durability of reimbursement rates. On May 4, 2026, GeneDx disclosed missed Q1 results, cut 2026 guidance from $540-555M to $475-490M, and took a $31.3M goodwill impairment charge on the $36.5M Fabric Genomics acquisition. The stock fell 49% ($33.42 per share) on the news. The deadline to seek lead plaintiff appointment is August 3, 2026.

Law firm Levi & Korsinsky has filed a class action lawsuit against Photronics, Inc. alleging the company made materially false statements about its product pipeline and demand while concealing critical bottlenecks. Following the company's May 28, 2026 earnings announcement revealing a 11% sequential IC revenue decline and missed guidance, Photronics' stock plummeted 36.42% in a single day. The lead plaintiff deadline is set for September 4, 2026.

Hub Group, Inc. faces a securities fraud lawsuit after restating financial statements due to approximately $77 million in understatements of purchased transportation costs and accounts payable. The company's stock fell 18% in February 2026 and an additional 13% in May 2026 following disclosure of material misstatements in its 2023, 2024, and 2025 financial reports. Investors who purchased shares between April 28, 2023, and May 11, 2026, may be eligible to recover losses.

Kirby McInerney LLP has filed a securities fraud class action lawsuit against Nano-X Imaging Ltd. on behalf of investors who purchased securities between March 31, 2025 and April 17, 2026. The lawsuit alleges that Nano-X overstated operational efficiency gains and product demand while concealing poor alignment between production and actual demand, leading to increased operating expenses and cash burn. On April 20, 2026, Nano-X disclosed a $17.5 million impairment charge related to restructuring its Korean manufacturing facility and announced its CFO's departure, causing the stock to decline 25% from $2.85 to $2.15 per share.

A securities fraud class action lawsuit has been filed against ADMA Biologics for allegedly engaging in channel stuffing, undisclosed related party transactions, and lacking adequate internal controls. Following a March 2026 short seller report by Culper Research alleging revenue manipulation through excess product stocking with extended payment terms, ADMA shares declined approximately 46% over three trading days. The lawsuit covers investors who purchased securities between August 9, 2024 and March 25, 2026.

Block & Leviton is investigating Cerebras Systems Inc. (NASDAQ: CBRS) and Primoris Services Corp. (NASDAQ: PRIM) for potential securities law violations. Cerebras' stock fell over $40 per share following disappointing Q1 2026 earnings results, while Primoris shares have also declined significantly. Investors who purchased shares and experienced losses are encouraged to contact the firm.

Law firm Levi & Korsinsky has filed a class action lawsuit against ZoomInfo Technologies Inc. on behalf of investors who purchased securities between November 3, 2025 and May 11, 2026. The complaint alleges the company made materially false statements about its growth and customer retention while concealing adverse facts about slowing growth and weakening downmarket segment performance. ZoomInfo's stock price fell approximately 33% following the announcement of disappointing Q1 2026 results and reduced 2026 guidance. The lead plaintiff deadline is set for August 24, 2026.

Univest Securities completed a registered direct offering of $1.479 million for EShallGo Inc. (NASDAQ: EHGO), selling 454,968 Class A ordinary shares at $3.25 per share to institutional investors. The offering was conducted under a shelf registration statement previously declared effective by the SEC.

A class action lawsuit has been filed against Peabody Energy Corporation for allegedly providing false and misleading statements about its Centurion mine operations. The company failed to disclose material adverse facts about production delays, leading to significant stock price declines after guidance cuts in March and May 2026. Investors who purchased BTU stock between October 14, 2024 and May 4, 2026 are eligible to participate, with a lead plaintiff deadline of August 24, 2026.

Kirby McInerney LLP has filed a securities fraud class action lawsuit on behalf of PicS N.V. investors who purchased shares during January 27 - June 5, 2026. The lawsuit alleges that PicS materially misrepresented its credit evaluation procedures and portfolio quality in its January 2026 IPO prospectus. Following the IPO at $19 per share, the stock declined over 50% as the company disclosed significant credit deterioration, including a Stage 3 loan ratio of 13% and elevated non-performing loan rates. The deadline to request lead plaintiff appointment is August 4, 2026.

Activist shareholder Howard Todd Horberg, holding 5.61% of Equus Total Return, Inc. (NYSE: EQS), has filed a Schedule 13D challenging the board's stewardship. The filing highlights five consecutive years of net investment losses, no dividends since 2009, a 65% decline in net asset value over two years, and executive compensation of $1.87 million while the company faces going-concern warnings. Horberg calls for suspension of automatic salary escalators, an independent compensation review, and a strategic review including potential merger or acquisition to address the company's concentrated portfolio and excessive overhead.

Brodsky & Smith law firm has announced investigations into multiple merger transactions, including Apogee Therapeutics (acquired by AbbVie for $135.11/share), Roku (acquired by Fox for $160/share), TruBridge (acquired by Inventurus for $26.25/share), and Organon (acquired by Sun Pharmaceutical for $14/share). The investigations focus on whether the respective boards breached fiduciary duties by failing to conduct fair processes and whether deal consideration provides fair value to shareholders.

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).

Iran closes Strait of Hormuz over ceasefire violations - MEHR  Reuters

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties to shareholders. The investigations concern AstroNova (being acquired by Arcline for $29.00/share), Open Lending (being acquired by ANV Group for $3.15/share), Huntsman (merging with Olin in a stock exchange), and Standard BioTools (being acquired by Treeline Biosciences). The firm is seeking shareholders to discuss whether fair processes were conducted and fair value provided.

Law firm Levi & Korsinsky has filed a class action lawsuit against Embecta Corp. for allegedly providing misleading guidance and concealing material adverse facts about its fiscal results. The company's stock plummeted 57.8% on May 5, 2026, after revealing a 14% revenue decline and lowering 2026 guidance, particularly due to weakness in pen needle sales. The lead plaintiff deadline is set for August 17, 2026.

Brodsky & Smith law firm is investigating four merger transactions to determine whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Simulations Plus ($18.50/share), Roku ($160.00/share), TruBridge ($26.25/share), and Organon ($14.00/share).

Monteverde & Associates PC is investigating four merger transactions on behalf of shareholders: Citizens National Corporation's sale to Peoples Bancorp, National Storage Affiliates Trust's sale to Public Storage, CNB Bank Shares' sale to HBT Financial, and Esquire Financial Holdings' merger with Signature Bancorporation. Shareholders are encouraged to contact the firm for free consultation regarding potential concerns with these deals.

Ascentage Pharma announced seventeen clinical updates from its core assets at the 31st European Hematology Association Congress, including eight poster presentations. Key data showed olverembatinib demonstrated deep and durable responses in chronic myeloid leukemia (CML) patients resistant to first-line therapy and robust clinical response in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Lisaftoclax showed promising efficacy in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid neoplasms, with a chemotherapy-free combination regimen yielding encouraging results in pediatric patients with relapsed/refractory Ph+ ALL.